Skip to main content

Day: February 13, 2023

Great Elm Group Reports Fiscal 2023 Second Quarter Financial Results

Company to Host Conference Call at 9:00 a.m., ET, on February 14, 2023 WALTHAM, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) — Great Elm Group, Inc. (“we,” “our,” “GEG,” or “Great Elm”), (NASDAQ: GEG), an alternative asset manager, today announced financial results for its fiscal second quarter ended December 31, 2022. Transformational TransactionsOn January 3, 2023, GEG sold its Durable Medical Equipment (“DME”) business for $80 million. After settling all obligations, the transaction resulted in approximately $26 million in net cash proceeds and 346,028 shares of Quipt common stock. On December 30, 2022, GEG entered into an agreement to sell 61% of the equity interests in Forest Investments, Inc. (“Forest”) and on January 17, 2023 it exercised a put right for the remaining 19% of the equity interests in Forest for aggregate cash...

Continue reading

Vornado Announces Fourth Quarter 2022 Financial Results

NEW YORK, Feb. 13, 2023 (GLOBE NEWSWIRE) — Vornado Realty Trust (NYSE: VNO) reported today: Quarter Ended December 31, 2022 Financial Results NET LOSS attributable to common shareholders for the quarter ended December 31, 2022 was $493,280,000, or $2.57 per diluted share, compared to net income attributable to common shareholders of $11,269,000, or $0.06 per diluted share, for the prior year’s quarter. Adjusting for the items that impact period-to-period comparability listed in the table on the following page, net income attributable to common shareholders, as adjusted (non-GAAP) for the quarter ended December 31, 2022 was $19,954,000, or $0.10 per diluted share, and $22,977,000, or $0.12 per diluted share for the quarter ended December 31, 2021. FUNDS FROM OPERATIONS (“FFO”) attributable to common shareholders...

Continue reading

Cytek® Biosciences to Acquire Flow Cytometry and Imaging Business from DiaSorin

Sale of assets related to Flow Cytometry & Imaging (FCI) Business Unit Acquisition will expand Cytek’s product portfolio to include imaging and menu-based application driven flow cytometry to provide full cell analysis solutions to its customers Transaction is in line with DiaSorin’s strategic priorities communicated to the market after Luminex acquisition Employees associated with commercial, operations, R&D and supporting functions expected to join CytekSALUGGIA, Italy and FREMONT, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) — DiaSorin (FTSE MIB: DIA) and Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that Luminex Corporation, a wholly owned subsidiary of DiaSorin, has signed an agreement with Cytek to sell substantially all of its assets related to the Flow Cytometry & Imaging (FCI) business unit. The sale...

Continue reading

MDxHealth Announces UnitedHealthcare to Provide Commercial Coverage for the Genomic Prostate Score (GPS) Test

NEWS RELEASE 13 FEBRUARY 2023, 4:00PM ET / 22:00 CET UnitedHealthcare singles out mdxheath’s GPS test as its only commercially-covered test to risk stratify men newly diagnosed with localized prostate cancer IRVINE, CA, and HERSTAL, BELGIUM – February 13, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today announced that UnitedHealthcare will cover the mdxhealth Genomic Prostate Score (GPS) test (formerly Oncotype DX GPS) under UnitedHealthcare’s commercial policies to assist with treatment decisions for individuals newly diagnosed with localized prostate cancer and meeting coverage criteria. Michael K. McGarrity, CEO of mdxhealth, commented: “We are very pleased to announce that UnitedHealthcare, the largest private health insurer in the United States, will provide coverage for our Genomic...

Continue reading

Joint Statement by Sorrento Therapeutics, Inc. and Scilex Holding Company on Today’s Isolated Chapter 11 Filing By Sorrento Therapeutics, Inc.

SAN DIEGO and PALO ALTO, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) and an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, together with Sorrento, issued the following statements: Henry Ji, Ph.D., Chairman and Chief Executive Officer of Sorrento, commented: “Today, Sorrento Therapeutics, Inc. and its wholly-owned direct subsidiary, Scintilla Pharmaceuticals, Inc. (“Scintilla”), commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas (the “Bankruptcy Court”).  While Scilex is...

Continue reading

RJD Green Inc.’s Management Discusses 2022 Year-End Results and 2023 Growth

Tulsa, OK, Feb. 13, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — RJD Green Inc. (OTCPK: RJDG) CEO Ron Brewer updates shareholders on 2022 year-end results and targeted 2023. Dear Valued RJD Green Shareholders, As we have finished 2022 and are now in 2023, RJD Green’s management team would like to take the opportunity to update all existing and potential shareholders with the latest information on developments with the Company. Please be advised – this letter is not a substitute for reviewing our press releases and SEC filings. Some of this update is opinion – please note the forward-looking statements disclosure. We hope to simplify the complexity and put our latest news items in context and keep you updated on our activities and events that may not rise to the level of a press release or SEC filing. We continue to work...

Continue reading

ILUS Confirms the Incorporation of Its Defense Subsidiary, Hyperion Defense Solutions

NEW YORK, NY, Feb. 13, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – ILUS International Inc. (OTC: ILUS) is a Mergers and Acquisitions company focused on acquiring and growing companies in the public safety, industrial, defense and renewable sectors. The company has incorporated Hyperion Defense Solutions to roll out its defense sector growth through several acquisitions and partnerships which are currently in progress. ILUS co-founded Hyperion Defense Solutions (Hyperion) alongside two experienced and esteemed British military veterans, Chris Derbyshire, and Tim Grey. Through their combined 34 years of military service and 22 years holding senior roles in the defense sector, they have amassed a wealth of technical expertise and senior level contacts as well as an acute understanding of defense customer requirements and military...

Continue reading

SEER’S MV TECHNOLOGIES RECEIVES CONTRACTS FOR MORE THAN $2MM

COVERING MEDIA REPLACEMENT AND FIVE RENEWABLE BIOGAS PROJECTS IN CANADA AND THE US MV HAS $22 MILLION IN PROJECT BIDS OUTSTANDING MV Technologies contracts to design and install its H2S removal systems in five new biogas/RNG projects and recently received a new contract to replace approximately $600,000 of media annually in addition to its ongoing annual replacement media requirements of over $1.2MM. Currently, MV has outstanding biogas project bids valued at approximately $22MM for additional systems worldwide. BROOMFIELD, CO, Feb. 13, 2023 (GLOBE NEWSWIRE) — Strategic Environmental & Energy Resources, Inc. (SEER) (OTCQB: SENR), a provider of environmental, renewable fuels and industrial waste stream management services, has been recently awarded multiple purchase orders totaling more than $1.5M for the design and installation...

Continue reading

Genius Group Releases Schedule of Shareholder Actions

SINGAPORE, Feb. 13, 2023 (GLOBE NEWSWIRE) — Genius Group Limited (NYSE American: GNS) (“Genius Group” or the “Company”), a leading entrepreneur edtech and education group, releases today a schedule of shareholder actions: Wednesday, February 15th, 4.15pm EST: Virtual Investor Meeting The Company’s CEO, Roger Hamilton, will hold a virtual investor meeting to provide Investors with an update on the company, including an overview of Genius Group’s curriculum, Metaversity & A.I. development plans, details of the Company’s recently spin-off of Entrepreneur Resorts Ltd, the process for shareholders to follow to redeem their $10 per share NFT coupons and an opportunity to answer questions and respond to shareholder enquiries. A press release with details about the virtual investor meeting was released on February 6th, 2023 and can...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.